NEUMORA THERAPEUTICS, INC.
NASDAQ: NMRA (Neumora Therapeutics, Inc.)
Kemas kini terakhir: 5 jam lalu3.02
0.02 (0.67%)
| Penutupan Terdahulu | 3.00 |
| Buka | 2.96 |
| Jumlah Dagangan | 1,075,887 |
| Purata Dagangan (3B) | 1,625,888 |
| Modal Pasaran | 513,214,112 |
| Harga / Buku (P/B) | 3.92 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 9 Mar 2026 |
| EPS Cair (TTM) | -1.61 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.41% |
| Nisbah Semasa (MRQ) | 8.98 |
| Aliran Tunai Operasi (OCF TTM) | -199.43 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -108.00 M |
| Pulangan Atas Aset (ROA TTM) | -48.51% |
| Pulangan Atas Ekuiti (ROE TTM) | -79.05% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Neumora Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.5 |
| Purata | -0.63 |
|
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 27.57% |
| % Dimiliki oleh Institusi | 60.62% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Softbank Group Corp. | 31 Dec 2025 | 6,429,720 |
| Mic Capital Management Uk Llp | 31 Dec 2025 | 4,460,700 |
| Point72 Asset Management, L.P. | 31 Dec 2025 | 3,673,839 |
| Wellcome Trust Ltd (The) As Trustee Of The Wellcome Trust | 31 Dec 2025 | 3,309,123 |
| Iconiq Capital, Llc | 31 Dec 2025 | 2,559,090 |
| Lunate Capital Ltd | 31 Dec 2025 | 2,124,143 |
| Johnson & Johnson | 31 Dec 2025 | 1,849,445 |
| Renaissance Technologies Llc | 31 Dec 2025 | 1,445,902 |
| Ikarian Capital, Llc | 31 Dec 2025 | 1,278,408 |
| Julat 52 Minggu | ||
| Median | 8.00 (164.90%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Leerink Partners | 12 Jan 2026 | 8.00 (164.90%) | Beli | 2.22 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Feb 2026 | Pengumuman | Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 |
| 05 Jan 2026 | Pengumuman | Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones |
| 05 Jan 2026 | Pengumuman | Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |